CureVac is a pioneering biotech company focused on mRNA drugs for oncology and vaccines. In biotech, value derives from research quality, patent strength, and clinical success probability, not current ...

Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 First participant dosed in seasonal flu Phase 2 study with ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 11, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ...

The University of Texas MD Anderson Cancer Center and CureVac N.V. today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines. The collaboration creates ...

Issuer: CureVac / Key word(s): Conference/Study CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress 09.09.2024 / 13:00 CET/CEST The issuer is solely ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based ...

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 6, 2023 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ...

Acuitas said it collaborated with CureVac to develop vaccine technology CureVac accused of omitting Acuitas scientists from patent applications Nov 14 (Reuters) - Biotech company Acuitas Therapeutics ...

Issuer: CureVac / Key word(s): Restructure of Company/Strategic Company Decision CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities 03.07 ...

April 24 (Reuters) - German biotech company CureVac sued Moderna in Delaware federal court on ‌Friday, alleging that Moderna's COVID-19 vaccine Spikevax ‌infringed CureVac patents related to messenger ...

CureVac focuses on tumor immunotherapy, using messenger RNA (mRNA) therapies. The German company said on Tuesday that it had dosed its first patient in a phase 1 trial for its investigational cancer ...

CureVac's non-coding RNA oncology candidate, CV8102, is being assessed in a fully recruited dose-escalation and expansion Phase 1 study to confirm safety, tolerability, and efficacy as a single agent ...